A new University of Leicester study reveals that screening people who are at risk of developing diabetes could be a cost-effective health policy and improve the lives of patients.
In her inaugural lecture on Wednesday 12th November, Dr Clare Gillies of the Department of Health Sciences will reveal the results of her simulation study investigating the clinical and cost implications of screening people 'at risk' for impaired glucose intolerance and type 2 diabetes mellitus.
An important outcome of the work by Dr Gillies shows that early treatment and intervention resulting from this screening is potentially a cost-effective health policy for the UK.
Dr. Gillies is the winner of the School of Medicine Lauder Prize for best PhD. The prize will be awarded at the end of her lecture which starts at 5.30pm in the Frank and Katherine May lecture theatre, Henry Wellcome Building.
Her research involved comparing the cost and health implications of four different approaches to screening for impaired glucose tolerance and type 2 diabetes. These were:
i) no screening
ii) screening for type 2 diabetes alone resulting in health benefits from early diagnosis and treatment of the disease
iii) screening for impaired glucose tolerance and type 2 diabetes, allowing for both early treatment of diabetes and for lifestyle interventions to be applied to individuals with impaired glucose tolerance to reduce their risk of developing diabetes
iv) as for iii) but with pharmacological rather than lifestyle interventions
Dr Gillies developed a computer decision model using data from a number of sources to evaluate the cost and health implications of these four policies.
She said: "The model simulated a population with an increased risk of developing type 2 diabetes, who were aged 45 at the start of the model and thus time of screening. The model was run to estimate the cost and health implications over a 50 year time horizon, and the four different screening policies were then compared.
"Conclusions drawn from the work were that screening for type 2 diabetes and impaired glucose tolerance, with appropriate interventions for the latter, in an above average risk population at age 45, appears to be cost effective.